BREXAFEMME- ibrexafungerp tablet, film coated 
SCYNEXIS, INC.

----------

MEDICATION GUIDE
BREXAFEMME® [brex a fem]
(ibrexafungerp tablets) for oral use
What is the most important information I should know about BREXAFEMME?
BREXAFEMME may cause serious side effects, including:
  • Harm to your unborn baby. Treatment with BREXAFEMME during pregnancy can cause harm to your unborn baby.
Women who can become pregnant may be asked by their healthcare provider to take a pregnancy test before each treatment with BREXAFEMME. Women who can become pregnant should use effective birth control throughout the duration of treatment with BREXAFEMME and for 4 days after the last dose of BREXAFEMME. Talk to your healthcare provider about birth control methods that may be right for you.
See “Do not take BREXAFEMME if you:”
What is BREXAFEMME?
  • BREXAFEMME is a prescription medicine used to treat vaginal yeast infection and reduce the number of recurrent vaginal yeast infections in adults and adolescent females who have started their menstruation.
  • It is not known if BREXAFEMME is safe and effective in pre-adolescent females who have not started their menstruation.
Do not take BREXAFEMME if you:
  • Are pregnant or plan to become pregnant. BREXAFEMME may harm your unborn baby. Tell your healthcare provider if you are pregnant, think you might be pregnant, or plan to become pregnant.
  • Are allergic to ibrexafungerp.
Before you take BREXAFEMME, tell your healthcare provider about all of your medical conditions, including if you:
  • Are breastfeeding or plan to breastfeed. It is not known if BREXAFEMME passes into your breast milk. You and your healthcare provider should decide if you will take BREXAFEMME or breast feed.
BREXAFEMME may affect the way other medicines work, and other medicines may affect how BREXAFEMME works.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. 
How should I take BREXAFEMME?
  • Take BREXAFEMME exactly as your healthcare provider tells you to take it.
  • Take BREXAFEMME tablets by mouth with or without food.
What are the possible side effects of BREXAFEMME?
  • See “What is the most important information I should know about BREXAFEMME?”
The most common side effects of BREXAFEMME include headache, loose stools, nausea, stomach pain, dizziness, and vomiting.  
These are not all the possible side effects of BREXAFEMME.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store BREXAFEMME?
  • Store BREXAFEMME at room temperature between 68°F to 77°F (20°C to 25°C).
  • BREXAFEMME is supplied in child resistant packaging.
Keep BREXAFEMME and all medicines out of reach of children.
General information about the safe and effective use of BREXAFEMME.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use BREXAFEMME for a condition for which it was not prescribed. Do not give BREXAFEMME to other people even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about BREXAFEMME that is written for health professionals. 
What are the ingredients in BREXAFEMME?
Active ingredient: ibrexafungerp
Inactive ingredients:
Tablet core: butylated hydroxyanisole, colloidal silicon dioxide, crospovidone, magnesium stearate, mannitol, and microcrystalline cellulose. Tablet film coating: FD&C Blue #2, FD&C Red #40, hydroxypropyl cellulose, hydroxypropylmethyl cellulose 2910, talc and titanium dioxide.
BREXAFEMME is a registered trademark of SCYNEXIS, Inc.
Manufactured for: SCYNEXIS, Inc., Jersey City, New Jersey, 07302
©2022 SCYNEXIS, Inc.
For more information, call 1-888-982-SCYX (7299) or go to www.brexafemme.com

This Medication Guide -has been approved by the U.S. Food and Drug Administration       Revised: 11/2022

Revised: 12/2023
Document Id: 0b74c7e7-5f82-6243-e063-6294a90a9d08
Set id: c33be3a1-c4fd-512c-e053-2995a90a63eb
Version: 9
Effective Time: 20231201
SCYNEXIS, INC.